Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:17:42.516Z.
Calculation as of: 2026-10-06T21:17:42.516Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 05f4ae4a030aaca39f2691a5695262832c6d48704f11c5316ed8238ac0b3761e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$378849.00
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$667469.00
EV/EBIT Ratio
N/A
TTM Avg
4890412.78x
3Y Avg
4039256.57x
5Y Avg
4039256.57x
Market Cap
$110112.00
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $403887.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | N/A | 4890412.78x | 4039256.57x | 4039256.57x |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | 5.81x | 18.06x | 18.06x | 18.06x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
